国务院常务会议解读｜国务院常务会议审议通过药品管理法实施条例修订草案

Core Viewpoint - The State Council's meeting on December 31 approved the revised draft of the Drug Administration Law Implementation Regulations, emphasizing the importance of timely updates to drug management laws for ensuring public safety and promoting the healthy development of the pharmaceutical industry [1] Group 1: Drug Safety and Regulation - The revised regulations stress comprehensive supervision throughout the entire drug lifecycle, from research and development to usage, directly safeguarding public medication safety [1] - The meeting highlighted the need for stringent quality supervision across the entire drug supply chain and a strong crackdown on illegal activities in the pharmaceutical sector [1] Group 2: Industry Development - The regulations aim to activate industry development momentum by improving the drug review and approval system, particularly for breakthrough therapies, facilitating faster market entry for innovative drugs [1] - Encouraging pharmaceutical companies to invest in research and development, the regulations are expected to shift the industry focus from "generic" to "innovative" drugs, strengthening the domestic pharmaceutical sector [1] Group 3: Legal Foundation - The revisions are intended to solidify the legal framework for drug regulation, ensuring that stringent regulatory requirements are codified into law, thus providing a basis for enforcement [1]